Table 2 Procedural characteristics and outcomes
Characteristic | n (%) or median [IQR] |
|---|---|
Access site Common femoral vein Internal jugular vein | 148 (98.7) 2 (1.3) |
Access site complications Major & Minor | 0 7 (4.7) |
Time from parenteral anticoagulation initiation to CDMT | 1 [0–7] |
PE location Bilateral Saddle and main arteries Lobar | 150 (100) 78 (52) 72 (48) |
Initial anticoagulant Unfractionated heparin Low-molecular-weight heparin | 40 (26.7) 110 (73.3) |
Thrombectomy time, min | 37.5 [27–53] |
Estimated blood loss, mL | 350 [250–400] |
Post-procedure vasopressor use | 9 (6) |
Post-procedure hospital stay, days | 4 [3–7] |
Periprocedural ECMO utilization | 3 (2) |
Conversion to open surgery | 1 (0.67) |
Supplementation with CDF | 14 (9.3) |
Vena cava filter implantation | 6 (4) |
Anticoagulation at discharge Direct oral anticoagulant Vitamin K antagonist Low-molecular-weight heparin None | 106 (70.7) 10 (6.7) 23 (15.3) 3 (2) |